{
    "clinical_study": {
        "@rank": "90647", 
        "arm_group": [
            {
                "arm_group_label": "Irinotecan and nimotuzumab", 
                "arm_group_type": "Experimental", 
                "description": "Adminitration of irinotecan 150 mg/m2 IV once every 2 weeks and nimotuzumab 400 mg IV once weekly"
            }, 
            {
                "arm_group_label": "Irinotecan", 
                "arm_group_type": "Active Comparator", 
                "description": "Administration of irinotecan 150 mg/m2 IV once every 2 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate overall survival of nimotuzumab in combination with irinotecan\n      compared to irinotecan alone in subjects with EGFR overexpressed advanced gastric or\n      gastroesophageal junction cancer."
        }, 
        "brief_title": "Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Gastric Cancer", 
            "Gastroesophageal Junction Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This randomized, open-label, Japan and Korea collaborative, phase 3 study will evaluate\n      overall survival of nimotuzumab in combination with irinotecan compared to irinotecan alone\n      in subjects with EGFR overexpressed advanced gastric or gastroesophageal junction cancer.\n      Approximately 400 subjects will be randomized in a 1:1 ratio to receive irinotecan (control\n      group) or nimotuzumab and irinotecan (combination group). Nimotuzumab and/or irinotecan\n      should be continued until disease progression or intolerable toxicity. Nimotuzumab is\n      administered at 400 mg once weekly as an intravenous infusion and irinotecan is administered\n      at 150 mg/m2 once every 2 weeks as an intravenous infusion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Advanced or recurrent subjects with gastric or gastroesophageal junction\n             adenocarcinoma.\n\n          2. Subjects who experienced disease progression during first line or within 6 months\n             after the last dose of first line therapy.  The first line regimen must have\n             contained a 5-fluorouracil based agent and platinum agent.\n\n          3. Subjects with EGFR overexpression (2+ or 3+ in IHC)\n\n        Exclusion Criteria:\n\n          1. Subjects who have received irinotecan\n\n          2. Subjects who have received EGFR-directed therapy\n\n          3. Other active malignancy within the last 5 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01813253", 
            "org_study_id": "DE766-A-J302"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Irinotecan and nimotuzumab", 
                    "Irinotecan"
                ], 
                "description": "150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops", 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug", 
                "other_name": "Boryung irinotecan"
            }, 
            {
                "arm_group_label": "Irinotecan and nimotuzumab", 
                "description": "400mg IV once weekly until progression or unacceptable toxicity develops", 
                "intervention_name": "Nimotuzumab", 
                "intervention_type": "Drug", 
                "other_name": "DE-766"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Irinotecan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "epidermal growth factor receptor", 
            "second line"
        ], 
        "lastchanged_date": "August 12, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Nozomu Fuse"
                }, 
                "facility": {
                    "address": {
                        "city": "Kashiwa", 
                        "country": "Japan", 
                        "state": "Chiba", 
                        "zip": "277-0882"
                    }, 
                    "name": "National Cancer Center Hospital East"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aichi", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aomori", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ehime", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanagawa", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kumamoto", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagano", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nigata", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saitama", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shizuoka", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toyama", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hwansun", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeonju", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seongnam", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Japan", 
                "Korea, Republic of"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Japan-Korea Collaborative Phase 3 Study to Compare the Efficacy of Nimotuzumab and Irinotecan Combination Therapy Versus Irinotecan Monotherapy as Second Line Treatment in Subjects With Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer", 
        "overall_contact": {
            "email": "myhwang@kuhnil.com", 
            "last_name": "Mee young Hwang", 
            "phone": "82-2-2175-9763"
        }, 
        "overall_contact_backup": {
            "email": "ksshin@kuhnil.com", 
            "last_name": "Kyung sun Shin", 
            "phone": "82-2-2175-9758"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Korea: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Overall survival is defined as the time from the date of randomization to the date of the death from any cause.", 
            "measure": "Overall Survival", 
            "safety_issue": "No", 
            "time_frame": "Around 4.5 years  after first subject randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01813253"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression Free Survival is defined as the time from the date of randomization to the date of progression or death from any cause, whichever comes first.", 
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "Around 4.5 years after first subject randomization"
            }, 
            {
                "description": "Overall Response Rate is defined as the proportion of subjects with CR or PR in the best overall response.", 
                "measure": "Overall Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Around 4.5 years after first subject randomization"
            }, 
            {
                "description": "Disease Control Rate is defined as the proportion of subjects with CR, PR or SD in the best overall response.", 
                "measure": "Disease Control Rate", 
                "safety_issue": "No", 
                "time_frame": "Around 4.5 years after first subject randomization"
            }, 
            {
                "description": "Incidence of adverse events using latest CTCAE version 4 including minor version", 
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Around 4.5 years after first subject randomization"
            }
        ], 
        "source": "Kuhnil Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Daiichi Sankyo Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Kuhnil Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}